Around six weeks ago, Sun Pharmaceutical Industries, India's largest drugmaker, suffered a setback, which led to a selloff in the share. The US District Court of New Jersey granted Incyte's request for a preliminary injunction against Sun Pharma's launch of Leqselvi, a drug that treats alopecia.
For a film with such a grand vision, Sangeet Manapmaan needed more flamboyance to make it a memorable affair, feels Mayur Sanap.
Varun flying around in over-the-top stunts, showing off his dance moves, taking his shirt off and throwing dialogues in masala hero style. A padded-up star vehicle churned out for the nth time, sighs Mayur Sanap.
'We have to be prepared for the larger disruption that is likely to take place.'
Dr Reddy's Laboratories (DRL) share price plunged 6.66 per cent to Rs 1,203.50 per share on the NSE during Friday after analysts remained cautious on the company's Q3 performance and differed on its growth outlook. DRL's Q3 performance was viewed as subdued by some analysts when they adjusted it for one-time grants and incomes that the company received during the quarter.
Divya Nair/Rediff.com speaks to students and experts to find out whether it is better to study management in India or try for an international MBA.
The third edition of Fever FM's SuperWomaniya Awards 2024 was held at the ITC Grand Central hotel in Mumbai, and several stars made sure to walk the blue carpet.
The Congress on Friday hit out at the Election Commission after it rejected allegations over irregularities in the Haryana assembly polls, saying if the poll panel's goal is to 'strip itself of the last vestiges of neutrality', then it is doing a 'remarkable job' at creating that impression.
Drug major Sun Pharma is recalling over 34,000 bottles of a generic medication, used to treat high blood pressure, in the US market due to failed dissolution testing. As per the US Food and Drug Administration's Enforcement Report, the US-based arm of Sun Pharmaceutical Industries is recalling lots of Diltiazem Hydrochloride extended-release capsules which are used to treat angina, high blood pressure and some types of irregular heartbeats.
'It is not just the US and European opportunity, but it is a huge global opportunity.'
Nayar believes that the whole team has bought into Rohit and Gambhir's philosophy, including the two spin greats.
The tailwind of low price erosion in the US generics market, seen by domestic pharmaceutical companies in calendar year 2023 (CY23), may be reversing slowly, caution analysts. According to the latest data from US-based Centers for Medicare and Medicaid Services (CMMS), price erosion in calendar year 2024 (CY24) on a year-to-date (YTD) basis stood at a high of 15 per cent in the oral solid dosage (OSD) segment compared to a low of 1 per cent in CY23. This erosion, according to a report by Antique Stock Broking, was the highest in the last three years.
Analysts are expecting pharmaceutical companies to post sales growth of 10-11 per cent in the second quarter this financial year while the Ebitda (earnings before interest, tax, depreciation, and amortisation) margins are anticipated to improve by about 110 basis points. Ebitda improvement will be led by lower input costs because prices of active pharmaceutical ingredients (APIs) are 5-15 per cent lower year-on-year (Y-o-Y). Axis Capital said sales growth would be around 10 per cent, of which growth in the India market would be 11 per cent or so.
'Many were caught in a burnout race, chasing unsustainable growth without innovating.'
'A long-term investor with a 4 to 5 year horizon could invest in this theme via SIPs.'
Despatch just goes on and on, sighs Mayur Sanap.
Christmas romance, heists, thrillers, it's all there on OTT this week. Sukanya Verma lists her recommendations.
The change in labelling, which is seen as a part of government's effort to push generic drugs, will come into effect from September 13.
Donald Trump's Presidency of the United States will open new opportunities for India though certain sectors, especially pharma and IT, may face the heat if the incoming president decides to impose restrictions on imports and H1B visa regulations, experts said on Wednesday. Prime Minister Narendra Modi's friendly relationship with Trump will have a positive bearing on Indo-US relations but India may have to adapt its strategies to maintain cooperation in areas of mutual interest.
If Naam was made today, there wouldn't even have been enough audiences to boo it out of the halls, observes Deepa Gahlot.
It has become difficult for Ashwin to be even considered in the present scenario.
The judge further underlined that the minorities of the country had not only joined the mainstream but also were an important facet of it.
What makes Pushpa 2 float is Allu Arjun's magnetic performance. The actor really goes an extra mile to deliver the wildfire he promised, observes Mayur Sanap.
Research and development (R&D) spending by BSE 100 companies has grown steadily, rising from 0.89 per cent of revenue in FY20 to 1.32 per cent in FY24, averaging around 1 per cent over the period in-between, according to data compiled from Bloomberg and company annual reports. Also, these companies more than doubled their R&D spending in absolute terms over these five years: From Rs 25,041 crore to Rs 63,072 crore. While this reflects a prioritisation of innovation, corporate R&D investment remains relatively conservative.
Ask rediffGURU and PF and MF expert Janak Patel your mutual fund and personal finance-related questions.
Arjun Menon looks at the Top 10 South films that made an impact in 2024.
Experts believe the move will have little impact given limited production of generic drugs and authority of doctors in prescribing medicines.
Watch her in hand-to-hand combat, wielding guns, firing weapons and breaking bones like a beast in some of the sleekly done one-take sequences. She also owns some emotionally-charged moments within the same dramatic beat, observes Mayur Sanap.
Banerjee had on Wednesday said an amendment to existing laws will be passed in the state assembly next week to ensure capital punishment to convicted rapists.
Amaran is effective as a intimate, well researched piece of storytelling but does not try to break any new ground, observes Arjun Menon.
US markets have been very lucrative for the Indian pharma companies and many companies such as Ranbaxy and Dr Reddy's capitalised on this opportunity.
'API prices are dragging down margins and impacting our competitive ability.'
The pharmaceuticals sector is expected to post a revenue growth of around 13.5 per cent and a net profit growth of 30.3 per cent for the third quarter of 2023-24 (FY24), riding on the approval for niche drugs in the US market, fall in raw material prices and correction in shipping rates. In the healthcare segment, hospitals are expected to post revenue growth of 13 per cent during the coverage, while net profit growth would be around 37 per cent, ICICI Securities said in a note. However, the performance may not be comparable on a sequential basis due to the offset of the festive season in Q3FY24, the analysts noted.
Devara's self-appointed guardian of the sea unleashing violence as a means to end violence is purely Junior NTR fan-tasy, observes Sukanya Verma.
If you're a fan of the Transformer films already, you will be delighted with a hearty dose of nostalgia here but... Mayur Sanap adds a caveat.
'There is no reason why we should break this business up.'
Most of the pharma units are failing in documentation, and validation processes, and many don't have full-fledged quality control laboratories.
The BCG analysis shows Lupin gave an annualised average TSR of 29.9 per cent, ahead of the 18.4 per cent of Israel-based Teva Pharmaceutical, the world's largest generics maker. Teva is next on the list. Another Indian generic maker, Glenmark, occupies third position, with an 18 per cent TSR to its investors.
The company has entered into a tie-up with the US-based FSC Laboratories as its authorised generic partner for FSC's hypertension medicine Isoptin SR (Verapamil SR) in the US.
Closure would mean manufacturer might not be able to launch any new generic products in India in future.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances